PRA Health Sciences (PRAH) Set to Announce Quarterly Earnings on Tuesday

PRA Health Sciences (NASDAQ:PRAH) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of $1.02 per share for the quarter.

Shares of PRA Health Sciences (NASDAQ:PRAH) opened at $86.07 on Tuesday. PRA Health Sciences has a 12-month low of $57.72 and a 12-month high of $95.90. The stock has a market cap of $5,410.00, a PE ratio of 48.35, a P/E/G ratio of 1.16 and a beta of 0.31. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01.

In other PRA Health Sciences news, VP Linda Baddour sold 67,000 shares of PRA Health Sciences stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total transaction of $6,048,090.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider David W. Dockhorn sold 72,850 shares of PRA Health Sciences stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $90.83, for a total transaction of $6,616,965.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 217,815 shares of company stock valued at $19,690,710. Company insiders own 2.10% of the company’s stock.

PRAH has been the subject of several recent analyst reports. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Jefferies Group restated a “buy” rating and set a $95.00 price objective on shares of PRA Health Sciences in a research report on Thursday, October 26th. Robert W. Baird set a $94.00 price objective on shares of PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Mizuho set a $87.00 price objective on shares of PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, KeyCorp restated a “buy” rating and set a $93.00 price objective (up from $86.00) on shares of PRA Health Sciences in a research report on Monday, October 30th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. PRA Health Sciences presently has an average rating of “Buy” and an average price target of $92.31.

WARNING: “PRA Health Sciences (PRAH) Set to Announce Quarterly Earnings on Tuesday” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/pra-health-sciences-prah-set-to-announce-quarterly-earnings-on-tuesday.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply